



INVESTOR PRESENTATION

Capital raising

6 July 2020

Executive Summary

Pre COVID-19

- 1H'20 Services revenue grew by 44% to \$8.2m vs pcp
- At end of 1H'20, HYD was on track to achieve 15%+ YoY growth rate and deliver a full year cash operating profit¹ for FY20
- Signed distribution agreement with AngelMed, with first implants scheduled to begin in Singapore in March 2020

COVID-19 Impact

- HYD have seen a slowing and deferral in timing of some contracts – Q4 FY20 revenue expected to be ~25% below Q3 FY20
- FY20 Services revenue guidance ~\$14.7m (vs. \$13.3m in FY19)²
- Sustainable cost reduction initiatives within the core business have resulted in monthly cost reductions of ~20%+
- Temporary postponement of AngelMed early access scheme implants in Singapore due to surgery embargos

Outlook & Strategy

- Given cost saving initiatives in place, HYD anticipates cash operating profit¹ breakeven in FY21 on lower revenue levels than FY20
- Hydrix Medical first sales and implants of AngelMed devices to commence in Singapore immediately upon COVID-19 restrictions being lifted and potential first implants under early access schemes in Australia late 2Q FY21
- Strong future potential capital growth of Hydrix Ventures 'medtech innovations' portfolio assets

Capital Raising

- A\$3.0m capital raise via a:
 - A\$1.0m Placement; and
 - A\$2.0m fully underwritten 1 for 3 pro-rata non renounceable entitlement offer
- 1 free attaching option for every 3 new shares subscribed for with an exercise price of \$0.12, expiring on 31 July 2022
- Funds used to repay \$0.75m of loan with Pure Asset Management and strengthen the balance sheet

1. Cash operating profit is Earnings before Interest, Tax, Depreciation, Amortisation (EBITDA) and Share-based payments for a full year (excluding 'buy, build, invest' initiatives) and may vary on a quarterly basis

2. Excludes R&D rebate income



Hydrix – Business Overview

Hydrix is leveraging its powerful product innovation capability to capture more of the value it creates across multiple growth platforms

Hydrix Services

Product Design & Engineering Services

- Deliver world class product design, engineering & regulatory services to create market leading solutions which improve lives
- We apply years of know-how to:
 - (i) de-risk product development,
 - (ii) create market-leading solutions, and
 - (iii) accelerate go to market strategies
- Driven by our clients to be “match-fit” in product development, creating a powerful innovation capability for the Hydrix Group

Hydrix Ventures

Direct & ‘Equity for Service’ Investments

Leveraging deep commercial market insights and technical expertise to “*pick winning investments*” in high-potential medical technologies from large deal-flow


Hydrix Medical

Tech-rich Cardiovascular Products, Technologies & Services

Cardiovascular disease afflicts 14% of the global population, cause of 31% of deaths

Hydrix Medical's mission is to identify and distribute technology-rich cardiovascular products, technologies and services in Asia-Pacific markets that:

- Improve patient quality of life and well-being
- Provide a greater sense of freedom and mobility
- Potential to transform Hydrix through strong recurring product and monitoring services revenue growth



Hydrix Services: Global Expertise In Large & Growing Sectors

Creating leading products & innovations that transform markets

Medical Technologies

Portable X-Ray Machine

Hydrix was the primary development partner of the first carbon nanotube mobile x-ray platform.

Unique ultra-lightweight, mobile x-ray imaging systems for medical applications.

Guided client from 'concept' to 'commercialisation'.



Bio-separation Device

Hydrix developed a Bio-separation device for first application use in human invitro fertilization (IVF).



Industrial & Mining

Mining

Hydrix is driving technology innovation initiatives across the industry including new mechanisms to capture more detailed blast hole data.

These analytics help improve efficiencies in the use of explosives and operator safety.



Water & Sewer Management

Hydrix created a connected technology that revolutionises sewer system management from a desktop or remote device.



Defence & Rail

Defence Training

Hydrix is providing integration and engineering development services for the development of hardware and software elements of the airborne JTAC training system.

Hydrix is supporting algorithm development, AI & software development for the project



Mobile Jamming System

Hydrix developed an electro magnetic pulse electronics disabling system ('jamming')


Portable, ruggedized, low power, low noise, natural cooling, lightweight pack.



Hydrix Services: FY20 Financials

Revenue Growth¹ (\$m)

Delivered three-years of strong revenue



1. Excludes R&D tax rebates

Key Insights

- 1H'20 Services revenue grew by 44% to \$8.2m vs pcip
- FY20 Services revenue guidance ~\$14.7m (vs. \$13.3m in FY19)¹
- At end of 1H'20, HYD was on track to achieve 15%+ YoY growth rate and deliver a full year cash operating profit² for FY20
- Due to COVID-19, HYD have seen slowing and deferral in timing of some contract conversions – Q4 FY20 revenue expected to be ~25% below Q3 FY20
- Cost saving initiatives have resulted in monthly cost reductions of ~20%+
- Given cost reduction initiatives already in place, HYD anticipates cash operating profit² breakeven for FY21 on lower revenue levels than FY20
- Anticipate revenue growth in 2H FY21 as businesses globally get back to work and sentiment picks up
- The pipeline remains healthy at \$50+ million


1. Excludes R&D rebate income

2. Cash operating profit is Earnings before Interest, Tax, Depreciation, Amortisation (EBITDA) and Share-based payments for a full year (excluding 'buy, build, invest' initiatives) and may vary on a quarterly basis



Hydrix Ventures & Hydrix Medical: Buy, Build & Invest strategy

Hydrix Medical and Hydrix Ventures: Leveraging the skill sets within the Hydrix Services division to create and/or capture more of the value that it creates for its customers



Hydrix Medical - Overview

Hydrix Medical's mission is to identify & distribute tech-rich cardiovascular products, technologies and services in Asia-Pacific markets that will:

- Improve patient quality of life and well-being
- Provide a greater sense of freedom & mobility

Cardiovascular technologies for the Asia-Pacific market

hydrix[®]
medical



1st portfolio product is the **AngelMed Guardian**, an implantable monitoring device that can detect Acute Coronary Syndrome (ACS) events, including silent heart attacks.


A world 'first of kind' device, approved by the FDA who concluded the Guardian
"satisfies an unmet need."



Hydrix Medical - 1st Portfolio Product: The AngelMed Guardian®

World's first FDA approved **implantable heart attack alert system** using patented AI & Machine Learning algorithms

- FDA approved 1st generation device in April 2018. Undertaking FDA approval for upgraded longer-life battery (2x) for **commercial** device roll-out
- Device monitors heart **24X7** - detects heart-beat changes indicative of a potential heart attack, angina attack and arrhythmias
- Cardiovascular diseases affects **~14%** of population, est. for **31%** of all deaths worldwide, of these **85%** are due to heart attack and stroke...**45% of heart attacks are "Silent"**



Indicative Progress Milestones

USA

- FDA approval under IDE program, starting implants in clinical trial patients in H2 CY20
- 1st reference for 'paid implants' supporting FDA approval process (with new battery)
- FDA battery approval est. in 1QCY21
- Hydrix not entitled to US implant revenue

Singapore

- 1st implants approved under GN26 'special access'
- March 2020 implants temporarily postponed due to COVID-19 embargo
- Implants ready to commence once embargo lifted
- Full HSA regulatory approval process starts once FDA approves new battery

Australia

- Progressing "pre-TGA Approval" implants under Authorised Prescriber Scheme ("APS")
- Potential for paid implants late Q4CY20
- Full TGA regulatory approval process starts on FDA approving new battery
- TGA approval process c. 9-12 months

The AngelMed Guardian® - Value Proposition

1

Detects previously untreatable silent MIs, reduces symptom to door time & detects other heart anomalies



Improved patient care



Reduced costs

2

Reduces false positive hospital visits. Improved preservation of left ventricular status helps decrease long-term costs

3

The device data provides actionable information complimenting standard-of-care testing



Improved clinical experience



Improved health

4

The added confidence of heart monitoring lowers anxiety, improves sleep and helps patients to exercise



The AngelMed Guardian®

Large market opportunity in Asia Pacific

			Potential Market Penetration				Initial Target Markets
Region ¹	Population (m)	ACS Incidences p.a. ²	Annual Sales Volume (units)		Annual Sales Value (A\$) ³		
			1.0%	5.0%	1.0%	5.0%	
Australia	25.1	75,000	750	3,750	\$5.6m	\$28.1m	
Singapore	5.7	30,000	300	1,500	\$2.2m	\$11.3m	
Japan	126.9	300,000	3,000	15,000	\$22.5m	\$112.5m	
Malaysia	32.4	85,000	850	4,250	\$6.3m	\$31.9m	
New Zealand	4.8	18,000	180	900	\$1.4m	\$6.8m	
Hong Kong	7.4	12,000	120	600	\$0.9m	\$4.5m	
202.3		520,000	5,200	26,000	\$38.9m	\$195.1m	

AngelMed Guardian® market penetration can be achieved by leveraging pacemaker surgery know-how and existing infrastructure:

Efficacy / Risks

- Provides a diagnostic alert tool that is needed but not currently available

Addressable market

- Larger addressable market when compared to pacemaker / ICDs (est. 2x-3x)

Technical maturity:

- Pacemaker device implant risks are well known & accepted, & pacemaker lead surgical implant procedures well-practiced

Economics:

- USA pricing USD\$9k+. Pricing lower than double chamber pacemaker & ICDs. For 50%+ patients, the device cost is expected to be covered by private health insurance. Government medical device & surgical reimbursement schemes applications are underway
- Process underway to identify sub-distributors in markets including Japan

1. Distribution rights also include Thailand and Indonesia.


2. ACS (acute coronary syndrome)

3. Based on A\$7,500 device average sale price




Hydrix Medical: Cardiac Patient Vision


Patient monitoring



Managed Information



Clinical Benefits




Value Proposition: Sum of the Parts

Significant upside value potential when reviewing Hydrix on a sum of the parts approach...merit for each of the three divisions to be individually valued at greater than the Company's current raise market cap of ~\$7m

Hydrix Services

Product Design & Engineering Services



- FY20 revenue guidance ~\$14.7m (\$13.3m FY19)
- Cost saving initiatives have resulted in monthly cost reductions of ~20%+, sustainable in FY21 at current revenue levels
- \$50m+ opportunity pipeline
- Weighted with overseas medtech clients

Hydrix Ventures

Direct & 'Equity for Service' Investments



- Cash & committed in-kind cost base \$3.0m+
- Potential for 5x – 10x value uplift
- Key investments include:
 - ~15% equity: Cyder Surgical (orthopedic tool)
 - 7.5% equity: Cyban (brain trauma monitoring)
 - 4.6% equity: AngelMed (heart monitoring)
 - <1.0% equity: Memphisys (asx:mem) (bio-separation)

Hydrix Medical

Cardiovascular Products, Technologies & Services



- 1st portfolio product: AngelMed Guardian® device, world's 1st implantable heart attack alert device – FDA approved
- Acquired APAC distribution rights (8 countries)
- Targeting 1st implants in Singapore once COVID-19 restrictions are lifted
- \$8m/yr. sales if only 1% sales penetration of initial target markets Singapore & Australia, these account for <20% of total territory market potential
- Approx. 50% GP margin



Capital Raising



Capital Raising – Offer Details

Offer size & structure	<ul style="list-style-type: none"> • Placement to raise approximately A\$1.0m (“Placement”) • Fully underwritten, 1 for 3 pro-rata non-renounceable entitlement offer to raise approximately A\$2.0m (“Offer”) • Approximately 13.3 million new shares will be issued under the Placement and 26.5 million new shares will be issued under the Entitlement Offer (“New Shares”) • Participating shareholders will receive 1 free attaching option for every 3 new shares subscribed with an exercise price of \$0.12, expiring on 31 July 2022. Investors in the Placement will receive the same option terms • Options will be listed on the ASX • Henslow is acting as Lead Manager to the Placement and Underwriter to the Offer
Placement & Offer Price	<ul style="list-style-type: none"> • Placement & Offer price of \$0.075 per new share, representing a discount of: <ul style="list-style-type: none"> – 25.0% to the closing price of Hydrix’s shares of \$0.10 per share on 30 June 2020; and – 20.0% to TERP⁽¹⁾ of \$0.094
Placement Details	<ul style="list-style-type: none"> • The Company has received commitments under Placement; however as the Company has utilised its Placement capacity, settlement will be subject to shareholder approval
Offer Details	<ul style="list-style-type: none"> • The Entitlement Offer will open on 13 July 2020 and close on 23 July 2020 • Under the Entitlement Offer, Eligible Shareholders that take up their full Entitlement may also apply for additional New Shares in excess of their Entitlement (“Additional New Shares”)
Substantial Shareholder Intentions	<ul style="list-style-type: none"> • The Company’s largest shareholder (21%), John W King Nominees & Associates, along with Directors of the Company have indicated they will take up entitlements under the Offer
Use of Proceeds	<ul style="list-style-type: none"> • Offer proceeds will be used to repay \$0.75m of the Pure Asset Management loan and strengthen the balance sheet
Ranking	<ul style="list-style-type: none"> • New Shares and Additional New Shares issued under the Offer will rank equally with existing Hydrix shares
Record Date	<ul style="list-style-type: none"> • 7:00pm (AEST) Thursday, 9 July 2020

1. TERP is a theoretical price at which Hydrix shares trade immediately after the ex-date for the Offer. TERP is calculated by reference to Hydrix’s closing price of \$0.10 on 30 June 2020. TERP is a theoretical calculation only and the actual price at which Hydrix shares trade immediately after the ex-date for the Offer will depend on many factors and may not be equal to TERP.



Offer Timetable¹

Trading Halt	1 July 2020
Trading halt lifted and announcement of Entitlement Offer	6 July 2020
Record date for Entitlement Offer (7:00pm AEST)	9 July 2020
Entitlement Offer opens (9:00am AEST)	13 July 2020
Entitlement Offer closes (5:00pm AEST)	23 July 2020
Announcement of results of the Entitlement Offer & any Shortfall	27 July 2020
Settlement of any Shortfall	29 July 2020
Allotment of New Shares issued under the Entitlement Offer & shortfall	30 July 2020

1. This timetable is indicative only and is subject to change. Hydrix may alter the dates above, vary the Offer, at Hydrix's absolute discretion, subject to the ASX Listing Rules and the Corporations Act. All references to time are to Melbourne time.




Hydrix – a corporate snapshot

Major Shareholders	Shares (m)	%
John W King Nominees & Associates	16.7	21.0%
Jasper Capital P/L	3.0	3.8%
BNP Paribas Noms P/L (Acorn Capital)	2.8	3.5%
Flet Investments & Associates	2.8	3.5%
Peter Russell & Dominique Maurier	1.9	2.4%
Beachridge Advisory (Gavin Coote)	1.6	2.1%
Top 20	39.1	49%

Board & Senior Management	
Gavin Coote (GAICD)	Executive Chairman
Joanne Bryant	Non-Executive Director
Julie King (GAICD)	Non-Executive Director
Paul Wright (FAICD)	Non-Executive Director

Capital Structure (as of 30 June 2020)	
Ticker	HYD
Share Price	\$0.10
Shares on Issue (m)	79.6
Options and Performance Rights (m)	4.7
Pure Asset Mgmt Warrants (m)	8.0
Market Capitalisation (diluted) (A\$m)	\$9.2m



Board & Senior Management Team

Hydrix’s board and leadership teams have the experience and drive to ensure the success of the Company

Hydrix Board



Gavin Coote
Executive Chairman



Paul Wright
Non-Executive Director



Joanne Bryant
Non-Executive Director



Julie King
Non-Executive Director



Alyn Tai
*Corporate Counsel &
Company Secretary*

Hydrix senior management



Mandy Kelly
Chief People Officer



Alan Morris
*Group Marketing
Manager*



Michael Trieu
GM – Hydrix Services



Paul Kelly
*GM – Hydrix Medical
Medical Advisory Board*



Peter Lewis
*Executive Vice President &
Corporate Development*



Mark Langham
Group Financial Controller



Disclaimer

This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Company. The document is not intended to constitute an invitation or an inducement to engage in any investment activity. The presentation is not intended to constitute investment advice and should not be relied upon as such. This document is not intended as an offer or recommendation with respect to the purchase or sale of any securities in the Company.

The content and graphical illustrations contained in the presentation are provided for information purposes and should not be relied upon to form any investment decisions or to predict future performance. The Company is wholly reliant upon third parties for the accuracy and completeness of the information in the presentation and has no duty of care owed to you in relation to such information. Although the information expressed is provided in good faith and the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those included in the forward-looking statements include amongst others, unforeseen delays in product development, the timing and extent of any changes in the associated technology and the ability of the Company to meet its stated business goals.

Prospective investors should make their own independent evaluation of an investment in the Company or seek advice from their financial adviser, accountant, lawyer, stockbroker or other professional adviser before making any investment decision. Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of Section 766B of the Corporations Act, or otherwise. This presentation does not amount to, involve or imply a recommendation or a statement of opinion in respect of whether to buy, sell or hold a financial product.

Neither Hydrix nor any of its or their associates or any of the Company’s directors’ (Hydrix Group) shall have any liability whatsoever for: (a) investment advice; (b) a recommendation to enter into any transaction or strategy; (c) advice that a transaction or strategy is suitable or appropriate; (d) the primary basis for any investment decision; (e) a representation, warranty, guarantee with respect to the legal, accounting, tax or other implications of any transaction or strategy; or (f) to cause the Hydrix Group to be an advisor or fiduciary of any recipient of this report or other third party. None of the Hydrix Group shall be responsible for or have any liability to you for losses or damages (whether consequential, incidental or otherwise) arising in any way for errors or omissions in, or the use of or reliance upon the information contained in this document. To the greatest extent permitted by law, we exclude all conditions and warranties that might otherwise be implied by law with respect to the document, whether by operation of law, statute or otherwise, including as to their accuracy, completeness or fitness for purpose. Unauthorised copying of this document is prohibited.



A photograph of a modern, multi-story office building with large glass windows and balconies. The entire image is overlaid with a semi-transparent blue filter. In the foreground, there is a large sign with the Hydrix logo and tagline. A smaller sign on the building also displays the logo and address.

hydrix[®]

hydrix.com

30-32 Compark Circuit
Mulgrave VIC 3170
Australia

ASX:HYD

hydrix[®]

improving a billion lives